.svg)
Bronwyn has over 18 years executive experience in the health technology sector spanning commercialisation, venture capital, corporate development, capital raising and industry advocacy.
Formerly an Investment Director with leading healthcare VC, BioScience Managers, Bronwyn has managed over $65M of private and public equity capital raisings and been actively involved in over $30M of portfolio investments.
In 2017, Bronwyn founded ANDHealth, Australia’s only dedicated digital health accelerator & commercialisation support organisation. Now Australia’s leading health technology scale up accelerator, ANDHealth’s unique industry-led model has led to significant growth within Australia’s nascent digital health sector.
Bronwyn holds a number of health, technology and innovation advisory roles both in Australia and internationally. She has a Masters of Commercial Law from the University of Melbourne and a Bachelor of Commerce from the University of Western Australia. Bronwyn is Non-Executive Director and Chair of the Nomination & Remuneration Committee for Lumos Diagnostics.
Advisory roles:
• Australia New Zealand Leadership Forum Health Technologies Sector Group
• NSW Cyber Security Industry Standards Harmonisation Taskforce
• OUTBREAK Project Data Governance Advisory Committee
• RMIT University Health and BioMedical Sector Expert Research Advisory Group
• Swinburne University Innovation Precinct Advisory Board
• La Trobe University Digital Health Advisory Committee
With degrees in both Chemical Engineering and Immunology from the University of Melbourne, Grace has a track record in project management, clinical validation and commercialisation within the medtech and digital health sectors. She has previously held roles in the Project Management team at CSL Group and has been involved in the creation of multiple medtech businesses in her role as Business Development Manager of Grey Innovation. Grace is a co-inventor on a now ASX listed digital health technology developed with Monash University and has been actively involved in the development of health technologies from invention, through clinical trials, to commercialisation.
Grace has a passion for the nexus of invention, opportunity and business strategy; supporting good ideas reach their audience and survive when backed by strong and sustainable business strategy
With executive management and board level experience spanning government, commercial and academic sectors, Damien Millen brings strong management, advisory and industry sector knowledge to ANDHealth.
Damien has specialised in the areas of innovation, commercialisation, law and investment. With a demonstrable track record in achieving high yield investments for government and commercial parties, Damien is recognised for providing high-quality advice to government and the sector and leading high value projects within government and industry.
He has deep experience in developing and implementing complex agreements and projects on a state, national and international level and sourcing funding and development of innovative, early stage technologies. Damien has tertiary qualifications in law, biotechnology, technology management, finance and investment. He was admitted as a Legal Practitioner of the Supreme Court of NSW in 1998.
Claire holds a Bachelor of Business (Accounting) and is a member of the institute of Chartered Accountants of Australia and New Zealand and a certified member of the Governance Institute of Australia.
She is an experienced finance professional with over 15 years’ experience in senior financial roles within public and private entities across biotechnology, insurance and public practice sectors, including 9+ years ASX listed company secretary experience.
Claire has worked for both small and large companies, her most recent roles prior to joining Leydin Freyer being Director of Finance, Legal & HR and Company Secretary for Cogstate Limited. Her current portfolio of clients include, but are not limited to, Alcidion Limited, Invion Limited and Horizon 3 Biotech Pty Ltd.
Amabel has a depth of experience across the medical research and biopharma space, from pre-clinical R&D through to supporting commercialisation with business intelligence and analyst insights.
She has led proposal support at the University of Melbourne to growth the pipeline of MRFF submissions to secure revenue and funding success for impact-driven programs.
Previously as a consultant at Clarivate Analytics she supported the growth of the life sciences business in ANZ with custom projects, presales engagement and professional training and workshops to support business intelligence and regulatory compliance,
Amabel has hands-on R&D experience, with a PhD in vaccine design she has developed several novel vaccines and immunostimulatory agents and is a inventor for a anti-viral under commercial development. As a scientist for a University spin-out she project managed global studies for a new investigational oncology vaccine for a first in man phase 1 clinical trials.
Tayla graduated from Deakin University with a Bachelor of Health Sciences majoring in Health Promotion and Nutrition. Whilst living in the United Kingdom and working in Public Health as a Partnership and Digital Engagement Officer for a Healthy Lifestyle Service Provider Tayla has gained an insight and invaluable experience working with a diverse range of individuals, while learning how to be adaptive and utilise various communication styles.
Tayla is now implementing her skills from her past role to pursue a career in Digital Health as the Program Director at ANDHealth. Tayla has been at ANDHealth for the past year working closely with the VP Program Design to achieve ANDHealth's program activities, events and communications.
Tayla is profoundly passionate about helping others which is shown in her commitment to voluntary roles and wants to create a career that has a strong positive impact on others.
Chris Joins ANDHealth as Program Director for the Targeted Translator Research Accelerator (TTRA) initiative. Chris brings a wealth of experience spanning medical research, life science investment and the commercialisation of translational research, and is driven to improve patient outcomes by bridging innovative science with commercial expertise. Most recently, Chris was head of global asset search and evaluation at a Sydney based biotech investment firm, searching industry and academia for the most pioneering digital, device and therapeutic innovations.
Prior to this, Chris worked as a management consultant at EY and PwC where he helped entities from start-ups through to multinationals access critical grants and incentives designed to help industry-based R&D traverse funding valleys.
Chris holds a Bachelor of Animal and Veterinary Biological Sciences (Honours Class I) from the University of Sydney, and a PhD in Medicine (UNSW). Chris’ PhD, conducted at the Garvan Institute of Medical Research focused on elucidating the biological and molecular impacts, a poor diet and aging have on diseases such as insulin resistance, obesity, diabetes, as well as cardiac and neurological disorders.
Max is currently studying a Bachelor of Biomedicine at the University of Melbourne, majoring in Biotechnology. Being passionate about the intersection of biomedicine, technology and finance, Max has previously pursued internships at CSIRO Futures and ANDHealth to extend his knowledge beyond his university studies.
At CSIRO Futures, the strategic advisory arm of CSIRO, he was responsible for translating emerging scientific trends into strategic insights for industry and government clients spanning Health & Biosecurity, COVID-19 Recovery, Future Industries and Energy & Resources. His short time with CSIRO Futures saw him consult with internal CSIRO and government stakeholders, as well as external companies to address key business and innovation challenges.
In early 2021 Max was welcomed back to ANDHealth as an Industry Analyst and is excited to continue addressing commercialisation challenges within in the digital health ecosystem.
Rita is a highly organised and efficient Executive Assistant with over 10 years experience across a variety of industries including travel, consulting and health. She is a native German speaker and fluent in French. Rita also has a background in Business Administration and Office Management.
.svg)
Gavin has played a leading role in Medical Devices acrossAustralia, NZ and Asia Pacific for 35 years. He is driven to improve people’shealth by building businesses and organisations for the benefit of all.
With an extensive background as a senior commercial andexecutive leader in the Asia Pacific region Gavin has a track record of leadingorganizational growth and transformation in large and complex multinationalcompanies, which operate in sophisticated and highly regulated markets. He isbest known for developing and exporting outstanding leaders, building trulyinclusive and diverse workforces and growing engaged cultures.
Gavin’s philosophy of collaboration and service extendsto the broader community as a passionate advocate for efforts that improvehealth, literacy and education, particularly for Indigenous communities
Gavin is currently CEO of Omnigon, a private Australiancompany in the Ostomy Care market. He is also Chair of AND Health, Australia’s DigitalHealth accelerator, Australian Co-Chair of the Health Technology Sector Groupof the Australia/NZ Leadership Forum, Board Director for Bowel Cancer Australiaand Board Director for SAN Foundation. Gavin is a proud member of the Championsof Change Coalition Health group, sits on SBE Life Sciences Council and servesas an Ambassador for Rotary Oceania Medical Aid for Children (ROMAC).
Previously Gavin was Managing Director of Johnson &Johnson Medical Devices for Australia/NZ, Chair of the Medical TechnologyAssociation of Australia, Governor of American Chamber of Commerce and Co-Founder/Chairof Macquarie Park Business Coalition (in partnership with United Way).
Bronwyn has over 18 years executive experience in the health technology sector spanning commercialisation, venture capital, corporate development, capital raising and industry advocacy.
Formerly an Investment Director with leading healthcare VC, BioScience Managers, Bronwyn has managed over $65M of private and public equity capital raisings and been actively involved in over $30M of portfolio investments.
In 2017, Bronwyn founded ANDHealth, Australia’s only dedicated digital health accelerator & commercialisation support organisation. Now Australia’s leading health technology scale up accelerator, ANDHealth’s unique industry-led model has led to significant growth within Australia’s nascent digital health sector.
Bronwyn holds a number of health, technology and innovation advisory roles both in Australia and internationally. She has a Masters of Commercial Law from the University of Melbourne and a Bachelor of Commerce from the University of Western Australia. Bronwyn is Non-Executive Director and Chair of the Nomination & Remuneration Committee for Lumos Diagnostics.
Advisory roles:
• Australia New Zealand Leadership Forum Health Technologies Sector Group
• NSW Cyber Security Industry Standards Harmonisation Taskforce
• OUTBREAK Project Data Governance Advisory Committee
• RMIT University Health and BioMedical Sector Expert Research Advisory Group
• Swinburne University Innovation Precinct Advisory Board
• La Trobe University Digital Health Advisory Committee
Co-Founder, CEO, Chair, myKicks; Director, The Founder Institute; Venture Partner, Stone Ridge Ventures; Senior Advisor, Strategy, Growth and Financing, Inotek Corporation.
Charlie is an investor, adviser, and entrepreneur in the areas of innovation, science, research and commercialisation. He has over 20 years’ experience working in commercial, academic, and policy settings, and has been invited to speak at conferences in this field in the US, Europe and Asia.
Until early 2020, Charlie was the inaugural permanent CEO of the Office of Innovation and Science Australia (now the Office of Industry, Innovation and Science Australia), a role which supported the ISA Board in delivering its mandate to provide strategic advice, program oversight and public advocacy for Australia’s Science and Innovation system.
Charlie has a longstanding interest in the creation of new technology-based ventures, having previously been a member of the Investment Committee of the Venture Capital fund Uniseed, and more recently a co-founder of the Melbourne Accelerator Program. He serves on the investment committee for the commercialisation fund of the Murdoch Childrens’ Research Institute and is a mentor and investor at Moonshot Space Accelerator.
Melanie Leydin holds a Bachelor of Business majoring in Accounting and Corporate Law. She is a member of the Institute of Chartered Accountants, Fellow of the Governance Institute of Australia and is a Registered Company Auditor.
She graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and since February 2000 has been the principal of Leydin Freyer. The practice provides outsourced company secretarial and accounting services to public and private companies across a host of industries including but not limited to the Resources, technology, bioscience, biotechnology and health sectors.
Melanie has over 25 years’ experience in the accounting profession and over 15 years’ experience holding Board positions including Company Secretary of ASX listed entities. She has extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies and shareholder relations.
